PORTFOLIO
What the people we backed are working on.
Twenty-three companies, mostly entered at research to pre-IND. A few we picked up at IND or proof-of-concept when the science was right.
A FEW FROM THE PORTFOLIO
What the people we backed are working on.
Phosphatase-targeted small molecules
Anavo Therapeutics
Research → IND
Immuno-oncology combinations
Arcus Biosciences
Phase II
Regulated induced proximity (RIPTAC)
Halda Therapeutics
Pre-IND
TWENTY-THREE COMPANIES
The full list.
Every active investment, in legacy order. Three of them carry the editorial photo cards above; the rest get a name and a one-line summary, set in body type instead of logos.
Oncology
Anavo Therapeutics
Phosphatase-targeted small molecules for oncology and autoimmune.
Immuno-oncology
Arcus Biosciences
Adenosine and HIF-2α immuno-oncology combinations in phase II.
Oncology
Breakpoint Therapeutics
Synthetic-lethal DNA damage response programs for solid tumors.
Adjacent platforms
cellvie
Mitochondrial transplantation for ischemic and degenerative disease.
Oncology
Cullinan Oncology
Targeted oncology pipeline spanning small molecules and biologics.
Oncology
Delphia Therapeutics
Onco-pathway-driven precision medicines for solid tumors.
Oncology
Dren Bio
Bispecific antibodies engineered for myeloid-cell engagement.
Adjacent platforms
EpiBiologics
Targeted protein degradation through extracellular biologics.
Oncology
Halda Therapeutics
Regulated induced proximity (RIPTAC) for solid tumors.
Oncology
Harpoon Therapeutics
T-cell engager constructs for solid tumors and hematologic cancers.
Non-oncology
Incendia Therapeutics
Inflammasome-pathway modulators for inflammatory disease.
Adjacent platforms
LiberoThera
GPCR-targeted antibodies engineered against historically intractable targets.
Adjacent platforms
Light Horse Therapeutics
CRISPR-enabled target discovery for oncology programs.
Oncology
Magnet Biomedicine
Molecular-glue small molecules for proximity-driven oncology programs.
Immuno-oncology
NextCure
Novel immuno-oncology targets identified through proprietary FIND-IO.
Immuno-oncology
Normunity
Tumor-microenvironment immunology programs restoring normal immune function.
Oncology
ORIC Pharmaceuticals
Cancer-resistance-pathway small molecules across solid tumor indications.
Adjacent platforms
Orna Therapeutics
Circular RNA therapeutics for oncology and rare disease.
Oncology
STORM Therapeutics
RNA-modifying enzyme inhibitors for oncology.
Oncology
Theolytics
Oncolytic-virus platform engineered for solid-tumor delivery.
Adjacent platforms
Transition Bio
Condensate biology as a therapeutic platform across hard targets.
Oncology
Vertero
Stratified small molecules for resistant urology and oncology indications.
Immuno-oncology
Werewolf Therapeutics
Conditionally activated immuno-oncology biologics (PREDATOR platform).
PORTFOLIO BY THERAPEUTIC AREA
A representative cross-section.
Eight rows from the portfolio, with the stage we entered at and where the program sits now. The rest live in the grid above.
| Company | Therapeutic area | Modality | Stage at entry | Current stage |
|---|---|---|---|---|
| Anavo | Oncology | Small molecule | Research | IND-enabling |
| Arcus | Immuno-oncology | Biologic | Phase I | Phase II |
| Halda | Oncology | RIPTAC | Research | Pre-IND |
| Magnet Biomedicine | Oncology | Molecular glue | Research | Lead optimization |
| Normunity | Immuno-oncology | Biologic | Pre-IND | Phase I |
| ORIC | Oncology | Small molecule | Phase I | Phase II |
| Orna | Adjacent platform | Circular RNA | Research | Pre-IND |
| Werewolf | Immuno-oncology | Conditional biologic | Pre-IND | Phase II |
MORE RESOURCES
Diligence questions
The questions the partnership actually asks in the first hour, before anyone reaches for a term sheet.
Submit a proposal
A short form, a written response within ten business days. Including for the ones that are not a fit.
Co-development inquiries
For licensing, build-to-buy, and research-collaboration conversations with Taiho Pharmaceutical programs.